Design of a prospective, dose-escalation study evaluating the Safety of Pioglitazone for Hematoma Resolution in Intracerebral Hemorrhage (SHRINC)

International Journal of Stroke

Volumn 8, Issue 5, 2013, Pages 388-396

  Gonzales, Nicole R ^a   Shah, Jharna ^a   Sangha, Navdeep ^a   Sosa, Lenis ^a   Martinez, Rebecca ^a   Shen, Loren ^a   Kasam, Mallikarjunarao ^a   Morales, Miriam M ^b   Hossain, M Monir ^c   Barreto, Andrew D ^a   Savitz, Sean I ^a   Lopez, George ^a   Misra, Vivek ^a   Wu, Tzu Ching ^a   El Khoury, Ramy ^a   Sarraj, Amrou ^a   Sahota, Preeti ^a   Hicks, William ^a   Acosta, Indrani ^a   Sline, M Rick ^a   Rahbar, Mohammad H ^c,d   Zhao, Xiurong ^a   Aronowski, Jaroslaw ^a   Grotta, James C ^a   more..

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b MEMORIAL HERMANN HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Clinical trial; Intracerebral hemorrhage; MRI; Pioglitazone; Protocol; Therapy

Indexed keywords

PIOGLITAZONE; PLACEBO;

ADULT; AGED; ANEMIA; ARTICLE; BARTHEL INDEX; BRAIN EDEMA; BRAIN HEMATOMA; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COMMUNITY HOSPITAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG SAFETY; HUMAN; HYPOGLYCEMIA; LIVER TOXICITY; MAINTENANCE DRUG DOSE; MAXIMUM TOLERATED DOSE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CEREBRAL HEMORRHAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84879466173     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2011.00761.x     Document Type: Article

References (33)

1. Mayer SA, Rincon F. Treatment of intracerebral haemorrhage. Lancet Neurol 2005; 4 : 662-672.
2. Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol 2006; 5 : 53-63.
3. Morgenstern LB, Frankowski RF, Shedden P, Pasteur W, Grotta JC. Surgical treatment for intracerebral hemorrhage (STICH): a single-center, randomized clinical trial. Neurology 1998; 51 : 1359-1363.
4. Mendelow AD, Gregson BA, Fernandes HM etal. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005; 365 : 387-397.
5. Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke 1993; 24 : 987-993.
6. Lisk DR, Pasteur W, Rhoades H, Putnam RD, Grotta JC. Early presentation of hemispheric intracerebral hemorrhage: prediction of outcome and guidelines for treatment allocation. Neurology 1994; 44 : 133-139.
7. Yang GY, Betz AL, Chenevert TL, Brunberg JA, Hoff JT. Experimental intracerebral hemorrhage: relationship between brain edema, blood flow, and blood-brain barrier permeability in rats. J Neurosurg 1994; 81 : 93-102.
8. Suga S, Sato S, Yunoki K, Mihara B. Sequential change of brain edema by semiquantitative measurement on MRI in patients with hypertensive intracerebral hemorrhage. Acta Neurochir Suppl 1994; 60 : 564-567.
9. Xi G, Keep RF, Hoff JT. Erythrocytes and delayed brain edema formation following intracerebral hemorrhage in rats. J Neurosurg 1998; 89 : 991-996.
10. Xi G, Hua Y, Bhasin RR, Ennis SR, Keep RF, Hoff JT. Mechanisms of edema formation after intracerebral hemorrhage: effects of extravasated red blood cells on blood flow and blood-brain barrier integrity. Stroke 2001; 32 : 2932-2938.
11. Diab A, Deng C, Smith JD etal. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12, 14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002; 168 : 2508-2515.
12. Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 2000; 20 : 558-567.
13. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002; 82 : 615-624.
14. Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 2005; 191 : 331-336.
15. Luo Y, Yin W, Signore AP etal. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem 2006; 97 : 435-448.
16. Ou Z, Zhao X, Labiche LA etal. Neuronal expression of peroxisome proliferator-activated receptor-gamma (PPARgamma) and 15d-prostaglandin J2 - mediated protection of brain after experimental cerebral ischemia in rat. Brain Res 2006; 1096 : 196-203.
17. Pereira MP, Hurtado O, Cardenas A etal. Rosiglitazone and 15-deoxy-Delta12, 14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J Cereb Blood Flow Metab 2006; 26 : 218-229.
18. Zhao X, Strong R, Zhang J etal. Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia. J Neurosci 2009; 29 : 6186-6195.
19. Zhao Y, Patzer A, Gohlke P, Herdegen T, Culman J. The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Eur J Neurosci 2005; 22 : 278-282.
20. Zhao X, Zhang Y, Strong R, Grotta JC, Aronowski J. 15d-Prostaglandin J2 activates peroxisome proliferator-activated receptor-gamma, promotes expression of catalase, and reduces inflammation, behavioral dysfunction, and neuronal loss after intracerebral hemorrhage in rats. J Cereb Blood Flow Metab 2006; 26 : 811-820.
21. Schutz B, Reimann J, Dumitrescu-Ozimek L etal. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci 2005; 25 : 7805-7812.
22. Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 2005; 130 : 685-696.
23. Tureyen K, Kapadia R, Bowen KK etal. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem 2007; 101 : 41-56.
24. Shimazu T, Inoue I, Araki N etal. A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke 2005; 36 : 353-359.
25. Zhao X, Sun G, Zhang J etal. Hematoma resolution as a target for intracerebral hemorrhage treatment: role for peroxisome proliferator-activated receptor gamma in microglia/macrophages. Ann Neurol 2007; 61 : 352-362.
26. Maeshiba Y, Kiyota Y, Yamashita K, Yoshimura Y, Motohashi M, Tanayama S. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 1997; 47 : 29-35.
27. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356 : 2457-2471.
28. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010; 170 : 1191-1201.
29. Dormandy JA, Charbonnel B, Eckland DJ etal. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet 2005; 366 : 1279-1289.
30. Nakamura T, Yamamoto E, Kataoka K etal. Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. Stroke 2007; 38 : 3016-3022.
31. Aronowski J, Hall CE. New horizons for primary intracerebral hemorrhage treatment: experience from preclinical studies. Neurol Res 2005; 27 : 268-279.
32. O'Quigley J, Pepe M, Fisher L. Continual Reassessment Method: a practical design for phase 1 clinical trials in cancer. Biometrics 1990; 46 : 33-48.
33. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med 1995; 14 : 1149-1161.